hey @TimmyR30 perhaps novartis is just waiting on read outs on the many biomarkers before re-committing to this indication ...SI has not said they are giving up on Covid Ards...
yes novartis collaboration /partnership looks like focus is switching to non-covid ards but if results of our covid ards are promising there is always a chance we could see some sort of emergency approval...( afterall covid is not going away anytime soon)
A Non-covid ards trial if successful, could also open up the covid ards market via a label extension and we would have a more consistant cohort of patients ( as opposed to rapidly changing cohort during our recent trials ford covid ards)
but i will not right off our chances for an eventual approval in covid ards ....
Ann: Appendix 4C Quarterly Activity Report, page-76
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
-0.010(0.76%) |
Mkt cap ! $1.495B | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.33 | $1.28 | $1.819M | 1.396M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 29972 | $1.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 2008 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |